NFL Biosciences SAS Aktie
1,64EUR | 0,02EUR | 1,49% |
WKN DE: A3CTQ0 / ISIN: FR0014003XT0
Personal
2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|
Personal am Ende des Jahres | 1 | 2 | 4 | 3 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|
Summe Umlaufvermögen | 0 | 3 | 2 | 4 |
Summe Anlagevermögen | 0 | 0 | 0 | 0 |
Summe Aktiva | 1 | 4 | 2 | 4 |
Bilanz (in Mio. EUR) - Passiva
2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|
Summe Fremdkapital | 0 | 0 | 2 | 4 |
Summe Eigenkapital | 0 | 3 | 1 | 0 |
Summe Passiva | 1 | 4 | 2 | 4 |
Adresse
199 rue Hélène Boucher, 34170 Castelnau-le-Lez | |
Telefon | +33 (4) 11-93-76-67 |
Internet | http://www.nflbiosciences.com |
Management
Bruno Lafont
Chairman & Chief Executive Officer |
Dominique Côté
Independent Director |
Francis Ahner
Independent Director |
Guillaume Audema
Chief Financial Officer |
Ignacio Faus
Director & Managing Director |
Lara Babich
Head-Development & Manufacturing |
Violaine Desort Henin
Director-Medical Operations |
Yannick Plétan
Independent Director |